Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2022 07:05 ET | Source: uniQure Inc.

uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 11, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
October 03, 2022 07:05 ET | Source: uniQure Inc.

uniQure to Participate in Upcoming Industry Conferences in October

LEXINGTON, Mass. and AMSTERDAM, Oct. 03, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
September 06, 2022 07:05 ET | Source: uniQure Inc.

uniQure to Participate in Upcoming Industry Conferences in September

LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
August 08, 2022 07:05 ET | Source: uniQure Inc.

uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of...
June 23, 2022 07:05 ET | Source: uniQure Inc.

uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed...
June 22, 2022 16:34 ET | Source: uniQure Inc.

CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ: QURE), please note that all the...
June 22, 2022 07:05 ET | Source: uniQure Inc.

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
May 24, 2022 08:00 ET | Source: uniQure Inc.

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

LEXINGTON, Mass. and AMSTERDAM, May 24, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
May 11, 2022 07:05 ET | Source: uniQure Inc.

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass. and AMSTERDAM, May 11, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
May 02, 2022 16:45 ET | Source: uniQure Inc.

uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...